Dose and timing
One-tap logging at the moment of administration — formulation and strength pre-set. The timestamp anchors everything downstream.
For clinicians
Your patient is tracking their titration. Here's what that gives you.
Titrate is a patient-owned self-monitoring app. Your patient logs dose, timing, effect, and side-effects through the day; the app turns those entries into a structured, read-only report — built around the measures titration guidelines already ask you to record.
- Read-only link. No account, no install, no patient-identifying data required to view.
- Aligned with NICE NG87 recording guidance and CADDRA titration practice.
- Free validated instruments: ASRS v1.1 (WHO) and WFIRS (Weiss).
“How have the last few weeks been?” is a weak instrument.
Titration decisions are made from recall. Patients compress six weeks into “pretty good, I think,” and general questioning misses roughly three times as many side-effects as a structured checklist does [1]. NICE NG87 is explicit: symptoms and adverse effects should be recorded at baseline and at every dose change, on standard scales [2]. Almost nobody arrives with that record — because keeping it by hand is a part-time job, and it's a part-time job for a patient population defined by difficulty with exactly that kind of task.
Titrate moves the record-keeping to the moment it happens, so the appointment can be spent on the decision instead of the reconstruction.
Captured at the moment
What your patient records
Timed effect check-ins
Brief (<2 minute) prompts timed to the pharmacokinetics of the patient's formulation — capturing onset, peak, wear-off, and rebound windows rather than random samples [3]. Check-in burden is deliberately minimal; lower burden is directly associated with higher completion in EMA research [4].
Structured side-effect checklist
Modeled on the Barkley Side Effects Rating Scale (SERS), validated and stimulant-specific [1]: appetite, sleep, headache, mood, anxiety, tics, cardiovascular sensations — each severity-graded.
Weekly validated scales
ASRS v1.1 (the WHO adult self-report scale, free to use with attribution) for symptoms [5]; WFIRS for functional impairment across work, family, and life-skills domains — because medication response is judged by function, not symptom counts alone [6].
The report
What lands in your inbox (or your patient's hand)
A longitudinal dose-response curve
Symptom and side-effect severity plotted against dose changes over the reporting window — the answer to “is 40mg better than 30mg for this person?”
Within-day effect profile
Onset, peak, and wear-off timing drawn from time-stamped check-ins, mapped against the expected pharmacokinetic curve for the exact formulation [3].
Rebound / late-afternoon window
Stimulant rebound — the late-afternoon dip below baseline — is clinically documented, sharper on IR formulations, and chronically under-captured in clinic [7]. The report isolates the 4–6 PM window explicitly.
Side-effect incidence by dose
Structured-checklist frequency and severity per dose level, not a narrative summary.
Functional change
WFIRS-domain trend lines alongside symptom scores, so benefit and cost are visible in the same view.
See it, don't read about it
Open a de-identified sample report — the exact view a patient's link gives you.
Grounded in evidence
Built from the guidelines out, not from engagement metrics in
A 2025 systematic review found essentially no overlap between the published evidence on ADHD apps and the apps actually on the market [8]. Titrate was built in the opposite direction: every tracked signal exists because a guideline or peer-reviewed source says it moves the clinical picture — and nothing is tracked for engagement's sake.
NICE NG87
the report captures what the guideline says to record at baseline and each dose change [2]
ASRS v1.1 + WFIRS
validated instruments (WHO / Weiss), free to use — not proprietary, not paywalled [5][6]
Barkley SERS
the side-effect model behind the safety check-ins [1]
Published PK data
check-in timing per formulation from peer-reviewed pharmacokinetic literature [3]
Scope, by design
What Titrate will never tell your patient
Titrate does not diagnose, does not score severity into a recommendation, and does not suggest dose changes. It is a self-management tool, positioned within the FDA general-wellness safe harbor. Dose decisions remain entirely with you. Benchmarks, where shown, are descriptive (“others report…”), never prescriptive. Safety-critical entries (chest pain, palpitations, fainting, suicidal ideation) trigger a “contact your doctor / seek urgent care” message — never an app-generated suggestion.
This constraint is deliberate and permanent. An app that hints at dosing becomes a regulated medical device and, worse, a liability in your exam room.
Privacy posture
The patient owns the data. You see what they choose to show you.
Patient-controlled sharing
Reports reach you as read-only, revocable links the patient generates. You need no account to view one.
On-device by default
Data lives on the patient's device unless they opt into cloud sync. Nothing is shared without an explicit action by the patient.
Encrypted, minimal, exportable
Encryption in transit and at rest; the patient can export or delete everything at any time.
No secondary use without opt-in
Aggregate, de-identified data contribution is off by default and explicitly opt-in. No advertising, no data brokerage — for a health-data product, privacy is not a feature, it's the license to exist. (FTC Health Breach Notification Rule and GDPR Article 9 obligations are treated as baseline, not overhead.)
If the format is useful, point your titrating patients to it
Titration is the highest-friction phase of ADHD pharmacotherapy — weekly dose steps over 3–4 weeks [9], decided from whatever the patient can recall. Patients who arrive with a structured record make that phase shorter and safer. If a patient of yours is starting or adjusting stimulant medication, Titrate is free to start, takes under two minutes a day, and hands you back the record NICE NG87 assumes exists.
No clinician account required to view reports. A free clinician account lets you see linked patients' reports in one place — optional, never required.
Clinician FAQ
Does this replace rating scales I administer in clinic?
No. It's a between-visit record, not a clinical instrument. Think of it as the diary the guidelines assume exists, kept automatically.
Who sees my patient's data?
Only whoever the patient sends a link to. Reports are read-only and revocable. We hold no master view of patient data for clinicians, employers, or anyone else.
Does the app tell patients what dose to take?
Never. No diagnosis, no dose suggestions, no treatment claims. Safety-flag entries route to “contact your doctor.”
What does it cost?
Free for the core tracker and report. Patients can export or delete their data at any time.
I got a link from a patient. Do I need to sign up?
No. The link opens a read-only report in any browser. A free clinician account is available if you want linked patients' reports in one place — it's optional.
References
- Barkley Side Effects Rating Scale — PMC5938315 (structured checklists capture ~3× the side effects of general questioning)
- NICE Guideline NG87 — recording recommendations at baseline and dose change
- Stimulant formulation pharmacokinetics — Psychiatrist.com PCC review; T&F PK review (2019)
- EMA completion vs. burden — PMC12579720
- ASRS v1.1 — WHO/Kessler; free use with attribution (CADDRA)
- WFIRS — Weiss functional impairment scale; free use (CADDRA)
- Stimulant rebound — Cleveland Clinic; ADDitude clinical coverage
- JEHP 2025 systematic review — mHealth apps for ADHD, evidence/market overlap
- CADDRA Canadian ADHD Practice Guidelines — titration practice (weekly dose-stepping, 3–4 weeks)
Titrate is a self-management and wellness tool. It does not provide medical advice, diagnosis, or treatment. All prescribing decisions rest with the treating clinician.